aossa schreef op 18 januari 2016 15:21:
Galapagos (through Gilead Sciences & Morphosys)
This is true that the ‘Inflammatory Disease’ branch of Gilead is not very well known, as John Milligan, President & COO of Gilead, pointed out during his presentation. Though, Gilead is willing to develop that branch. The licensing of filgotinib from Galapagos is part of this strategy. The very selective JAK1 inhibitor is a potential best-in-class in RA. The safety is well assessed with more than 900 patients already treated, and it is taken orally. The key differentiator is its mechanism of action allowing to treat Crohn’s Disease as well as other indications (Ulcerative Colitis), as the phase II data presented last month tend to proof. Listen to the motivations of that decision explained by Milligan himself.
Audio Player
biotechradar.com/focus-j-p-morgan-con...The US FTC clearance has been granted for the licensing deal the day after Gilead’s presentation. Timingwise, both co-developpers are to meet the FDA for the ‘end-of-phase II’ in February. The phase III program will be presented with no doubt as well. The phase III in RA is to start mid 2016. Phase IIa data of filgotinib in Ulcerative Colitis will be next catalyst for Galapagos (expected around of the end of January).
Finally, Morphosys presented its impressive pipeline with more than 100 products, with MOR106 still in pre-clinical stage with Galapagos.